AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06761287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic resection
Description: Eligible patients will undergo endoscopic submucosal dissection (ESD) after two to six weeks of neoadjuvant treatment completion, depending on the used neo-adjuvant regimen. Procedures will be performed using the GIF EZ-1500 endoscope (Olympus America, Center Valley, PA, USA) and an electrosurgical unit (VIO 300 D; Erbe, Germany) to power the electrosurgical knife (1.5-mm DualKnife J, Olympus America). For mucosal incision, Endocut mode will be used, while Precise or Swift Coagulation modes will support submucosal dissection and hemostasis. An initial submucosal lift created by Glycéol Gel injection. The ERBE Flushing Pump (Erbe, Germany) will supply further submucosal lift during dissection through foot pedal-controlled, pressurized injections of methylene blue and saline solution delivered via the DualKnife J's ceramic-tipped tubing.
Study NCT06761287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short interval restaging
Description: Close follow-up and endoscopic re-evaluation four to eight weeks after the initial evaluation\* (\*defined as the first evaluation after completion of the neoadjuvant treatment)
Study NCT06761287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Description: This technique consists of the surgical complete removal of the rectum, together with the surrounding mesorectum lymphovascular fatty tissue (mesorectum).
Study NCT06761287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total mesorectal excision
Description: This technique consists of the surgical complete removal of the rectum, together with the surrounding mesorectum lymphovascular fatty tissue (mesorectum).
Study NCT06762145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (Corticosteroid)
Description: Intravenous Methylprednisolone 1mg/kg/d for 3 days started from the day on TAVR
Study NCT06762145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 3 days started from the day on TAVR
Study NCT06762353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-month supportive peri-implant care (SPIC)
Description: SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD >4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 3-month frequency after surgical treatment of peri-implantitis.
Study NCT06762353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 6-month supportive peri-implant care (SPIC)
Description: SPIC including update on smoking status, evaluation of the patient's adherence to self-performed oral hygiene procedures, full-mouth supra-gingival instrumentation around teeth, repeated sub-gingival instrumentation on sites presenting a PPD >4 mm with BoP/SoP or a PPD≥6 mm, supra-marginal instrumentation around implants, using an erythritol air abrasive system and interdental brushes, sub-marginal instrumentation on implants with BoP after deep probing by an erythritol air abrasive system and/or ultrasonic scaler provided at a 6-month frequency after surgical treatment of peri-implantitis.
Study NCT06761222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The use of ultrasound in central blocks
Description: Ultrasonography was conducted using a convex probe in the paramedian and transverse planes.
Study NCT06761729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet
Study NCT06762132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD33 CAR T-cells
Description: Each subject receive CD33 CAR T-cells by intravenous infusion
Study NCT06002854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP( platelet rich plasma) and Insulin human
Description: Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation
Study NCT05184101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated Heparin
Description: Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.
Study NCT05897190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine (RBMRNA-405)
Description: Dose A
Study NCT05897190 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac®
Description: Dose B
Study NCT05076760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEM-288 Intratumoral Injection
Description: Intratumoral injection of MEM-288, conditionally replicative oncolytic adenovirus vector encoding transgenes for human interferon beta (IFNβ) and a recombinant chimeric form of CD40-ligand (MEM40).
Study NCT05076760 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: anti-PD1 monoclonal antibody
Study NCT04384601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Perioperative chemotherapy will be administered according to description in two arms.
Study NCT04384601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Perioperative chemotherapy will be administered according to description in two arms.
Study NCT06225024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT
Description: Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
Study NCT06225024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BoNT A
Description: BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
Study NCT05265000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tSpinalStim
Description: Patients will undergo 12-21 sessions of spinal cord stimulation therapy (30 minutes per session, 3 times a week). Up to five round stimulating electrodes will be placed on the skin midline between spinous processes in cervical, thoracic and/or lumbar region, as cathodes and rectangular pads will be placed symmetrically on the skin over the iliac crests as anodes. The stimulator generates pain-free biphasic rectangular waveform with 1 ms width pulses filled with 5-10 kHz (kilohertz) carrier frequency. A range of stimulation intensities from 0-250 mA (milliamps) may be used. We expect that the stimulation intensities needed for therapeutic effect may differ based on individual's body mass index and/or the amount of subcutaneous fat present at the stimulation site.
Study NCT05491330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)
Description: 2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Study NCT05491330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir 150 mg + Ritonavir 100 mg (test)
Description: 2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Study NCT05491330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose)
Description: 2 tablets from Nirmatrelvir 150 mg + 1 tablet from Ritonavir 100 mg
Study NCT03900988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
Study NCT05976763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study NCT06225024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT A
Description: BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
Study NCT05606536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Solutions
Description: Locally approved crystalloid solution will be given at the predefined infusion rate
Study NCT05293613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave lithotripsy
Description: shock wave transmited from the device through patient body towards the stone to disintegrate it
Study NCT05249881 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Semaglutide Pen Injector
Description: All Diabetes mellitus type2 patients fulfilling the inclusion criteria, will receive 0.25mg Semaglutide injection per week and after two weeks dosage will be escalated to 0.5 mg/week for next 10 weeks.
Study NCT05482178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training plus hypocaloric diet
Description: The exercise program included 3 phases of progressive intervention: 1) Adaptation which included 3-4 days per week at 60% of maximum heart rate, 2) Development phase which included 5 days per week at 75-85% of maximum heart rate and the last one, 3) Maintenance phase which included 5 days per week at 75-90% of maximum heart rate. The control and follow up will be through text message exchanges at least once a week or as many as necessary.~On the other hand, the diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (>25g per day).
Study NCT05482178 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: The diet intervention consisted a caloric restriction of 20% of total energy estimated with Mifflin formula. The nutrients distributions are 50% for carbohydrates, 20% for protein and 30% for lipids, ensuring a sufficient intake of fiber (>25g per day).
Study NCT05922150 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: LLLT induces cellular biostimulation, speeds up tissue regeneration, enhances wound healing, and reduces pain and swelling through an anti-inflammatory effect. This is because the LLLT increases phagocytic activity, and the number and diameter of lymphatic vessels, decreases the permeability of blood vessels and restores microcapillary function
Study NCT05922150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozone gel
Description: ozone is effective antimicrobial (viricidal, bactericidal, and fungicidal). Other well-known benefits include immunological modulatory and stimulating effects and anti-inflammatory, biosynthetic, anti-hypoxic, and bioenergeticseffects
Study NCT05620004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium Bifidum Oral Product
Description: experimental group use Bifidobacterium Bifidum Oral Product and control group without Bifidobacterium Bifidum Oral Product
Study NCT05946785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
Study NCT05946785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: acetylcholine is perfused at 10 ascending concentrations (10\^-10M - 10\^-1 M) for 5 minutes each
Study NCT05946785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Study NCT05946785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin aspart
Description: insulin aspart is perfused at 5 ascending concentrations (10\^-8M - 10\^-4 M) for 10 minutes each
Study NCT06462534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Band-Frail Program
Description: Participants will complete 16 weeks of elastic band resistance training and diabetes management education.~Exercise Component:~The elastic band resistance training involves 12 exercises: chair sit-to-stands, seated chest press, seater upper back reverse fly, seated single arm row, seated single arm lateral raise, seated single arm bicep curl, seated single arm triceps extension, seated single leg quadriceps extension, standing hamstring curl, standing leg extension, and seated abdominal crunches.~There will be a one-minute rest between each set and a self-determined rest period between exercises.~Education Component:~A certified Diabetes Educator and registered dietitian will present information to participants covering topics relating to T2D management and nutritional information.
Study NCT06389734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual soft tissue release
Description: The manual soft tissue release includes muscle energy techniques and passive stretching, targeting the anterior scalene, upper trapezius, pectoralis major, pectoralis minor, and diaphragm.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time.
Study NCT06389734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release
Description: The myofascial release includes suboccipital muscle, anterior chest wall myofascial, and anterior neck myofascial.~Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time.
Study NCT06389734 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.
Study NCT06389734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.
Study NCT05694338 — intervention group
Intervention type: OTHER
Intervention: Frailty survey
Description: Frailty survey using the Clinical Risk Analysis Index (RAI-C).
Study NCT05910034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib+Envafolimab+Docetaxel
Description: This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
Study NCT05910034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab+Docetaxel
Description: This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
Study NCT05910034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: This is a multi-arm, randomized, controlled, multicenter, Phase II clinical study. Participants randomly assigned at a 1:1:1 ratio to three groups, and will be treated until disease progression, intolerance, withdrawal of consent or completion determined by the investigator.
Study NCT04656041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX/ nal-IRI
Description: A cycle will be two weeks (14 days) long, with FOLFOX/ nal-IRI administered on days 1-3.~The order of FOLFOX/ nal-IRI administration is as follows:~* 1) Liposomal Irinotecan free base via IV, predetermined dosage per protocol~* 2) Oxaliplatin via IV, predetermined dosage per protocol~* 3) Leucovorin via IV, predetermined dosage per protocol~* 4) 5-Fluorouracil via IV, predetermined dosage per protocol
Study NCT04656041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
Study NCT04656041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Paclitaxel and Carboplatin will be given concurrently with radiation therapy weekly (+/- 1 day).
Study NCT04656041 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Description: Chemoradiation with proton or photon radiation therapy concurrent with weekly Paclitaxel and Carboplatin for 5 weeks
Study NCT06305936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with 100% plant-based diet
Description: The intervention consists of three key components: 1) Educational materials (videos), 2) Participation in a cooking workshop introducing plant-based meals, complete with recipes, and 3) Daily delivery of plant-based dinner meals over a four-week period. The remaining meals during the period are modified by the participant to also adhere to a 100% plant-based composition.
Study NCT04791566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 1 mg/kg
Description: Dexamethasone 1 mg/kg administered as a single preoperative i.v. infusion over 10-15 min prior to general anaesthesia
Study NCT04791566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline
Description: 100 mL Physiologic saline administered as a single preoperative i.v., infusion over 10-15 min prior to general anaesthesia
Study NCT06017440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EXERCISE
Description: Participants will receive at 08:00 am a calibrated breakfast of 500kcal. They should not perform physical exercise during the day. They will be asked at 11 a.m. to cycle for 30 minutes at 65% of the maximal capacities and their energy expenditure will be measured by indirect calorimetry. At 11 a.m., teenagers will receive a calibrated meal of 800 kcal respecting the nutritional recommendations for this age. Questionnaires on feelings of hunger will be distributed to them at regular intervals. They will also be asked to complete a 10-minute computer exercise to assess their relationship to food before and after lunch (LFPQ. Leeds Food Preference Questionnaire, Liking/ wanting). Finally, from 60 minutes after the midday test meal, teenagers will have access to an ad libitum buffet for one hour.
Study NCT06017440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONTROL
Description: Teenagers should not perform any physical activity during the day and they will be asked to stay at 11 a.m., for 30 minutes, resting in a semi-supine position.
Study NCT04233554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Priorities Care
Description: Patients will participate in a structured conversation in which the facilitator (i.e. social worker) helps patients identify their health goals, measurable, actionable, realistic outcomes (e.g. walk ½ mile daily). Both practice and patient level data will be collected.
Study NCT04387175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carriere Motion 3D Class III Appliance
Description: The device made of stainless steel consists of a flexible bar with two pads at the end which are bonded bilaterally with composite resin to the lower second deciduous molar or the lower first permanent molar at the rear and the lower deciduous canine at the front. The base on the lower deciduous canine has a hook to which bilaterally elastic latex bands are connected with the vestibular tubes of the cemented bands on the upper deciduous second molars (Force 2 elastics ) or on the first permanent upper molars (Force 1 elastics), on whose palatine surface the a rapid maxillary expander is welded.
Study NCT04387175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facial mask
Description: The facial mask consists of a chin pad and frontal pad connected by a central steel bar. On the central bar there is a horizontal steel bar to which latex elastic bands are attached which develop 14 ounces of force. The elastics are connected to the rapid maxillary expander by means of two hooks welded on the bands of the second upper deciduous molars or the first upper permanent molars.
Study NCT04486482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: KB109 + Self Supportive Care (SSC)
Description: KB109 is a novel glycan
Study NCT04486482 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self Supportive Care (SSC) Alone
Description: Self Supportive Care (SSC) Alone
Study NCT03181087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical cord MSCs
Description: Participants will receive direct local intramuscular injection of 1\*10\^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
Study NCT03900988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose
Description: 5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.